What's Happening?
ILiAD Biotechnologies has successfully raised $115 million in a Series B funding round to advance the development of a new whooping cough vaccine, BPZE1. This vaccine is a live, attenuated pertussis vaccine delivered intranasally, licensed from the Institut
Pasteur de Lille and Inserm in France. The vaccine aims to provide long-lasting protection both mucosally and systemically, potentially offering a more natural and durable immune response. The funding round was led by RA Capital Management, with participation from Janus Henderson Investors, BNP Paribas, and other existing investors. The company plans to initiate a pivotal human challenge trial later this year, with results expected in 2027. This development comes amid rising cases of whooping cough in Europe and the U.S., attributed to lower vaccination rates and reduced population immunity.
Why It's Important?
The development of BPZE1 is significant as it addresses the growing public health concern of whooping cough, a disease characterized by severe coughing fits. The needle-free administration of the vaccine could improve vaccination rates by offering a more convenient and less invasive option. This could lead to increased population immunity and a reduction in disease transmission. The successful funding round underscores investor confidence in ILiAD's approach and the potential impact of their vaccine. Additionally, the focus on a more natural immune response could set a precedent for future vaccine developments, particularly in addressing diseases with declining vaccine uptake.
What's Next?
ILiAD Biotechnologies is set to begin a pivotal human challenge trial for BPZE1 later this year. The trial's outcome will be crucial in determining the vaccine's efficacy and safety, potentially leading to regulatory approval and commercialization. The company will likely continue to engage with regulatory bodies to ensure compliance and facilitate the vaccine's market entry. The success of this trial could influence public health strategies and vaccination programs, particularly in regions experiencing a resurgence of whooping cough.
